Scinovex
reviewTop 1% cited

Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy

Biochemical and Biophysical Research Communications · 2005 · Vol. 333(2) · pp. 328–335
Napoleone FerraraKenneth J. HillanWilliam Novotny
Angiogenesis and VEGF in CancerCancer, Hypoxia, and MetabolismCancer-related Molecular PathwaysBevacizumabAngiogenesisMedicineVascular endothelial growth factorCancer researchNeovascularizationMonoclonal antibodyImmunologyAntibodyChemotherapy

MeSH terms

BevacizumabAnimalsAntibodies, MonoclonalAntineoplastic AgentsClinical Trials as TopicHumansNeoplasmsNeovascularization, PathologicTreatment OutcomeAngiogenesis InhibitorsVascular Endothelial Growth Factor AAntibodies, Monoclonal, Humanized
Citations
965
FWCI
16.90
field-weighted impact
References
112
Percentile
100%
vs. same field & year
Citations per year
Cited by
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
New England Journal of Medicine · 2020 · 6,911 citations
Active targeting schemes for nanoparticle systems in cancer therapeutics
Advanced Drug Delivery Reviews · 2008 · 1,702 citations
Modes of resistance to anti-angiogenic therapy
Nature reviews. Cancer · 2008 · 2,901 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.

Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy · Scinovex